A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia
Status:
Completed
Trial end date:
2017-07-31
Target enrollment:
Participant gender:
Summary
This Phase 3 study assesses two drug regimens as the initial treatment of patients who are at
least 70 years of age and have newly diagnosed acute myeloid leukemia (AML) for whom the
doctor does not recommend the use of standard intensive treatment or the patient has decided
not to receive standard intensive treatment after being fully informed about its benefits and
risks by his/her doctor. The two drug regimens are sapacitabine administered in alternating
cycles with decitabine or decitabine alone. The purpose of the study is to learn which drug
regimen is more likely to keep AML in check as long as possible.